Clinical trials of new drugs for Alzheimer disease

Alzheimer disease (AD) accounts for 60–70% of dementia cases. Given the seriousness of the disease and continual increase in patient numbers, developing effective therapies to treat AD has become urgent. Presently, the drugs available for AD treatment, including cholinesterase inhibitors and an anta...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Journal of biomedical science Ročník 27; číslo 1; s. 18 - 13
Hlavní autoři:	Huang, Li-Kai, Chao, Shu-Ping, Hu, Chaur-Jong
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	London BioMed Central 06.01.2020 BioMed Central Ltd Springer Nature B.V BMC
Témata:	Advertising executives Alzheimer disease Alzheimer's disease Amyloidosis Anti-Alzheimer's disease agents Anti-amyloid Anti-tau Aspartate Atrophy Biomarkers Biomedical and Life Sciences Biomedicine Brain Cholinesterase Cholinesterase inhibitors Clinical trials Clinical trials of drugs Cognitive ability Dementia Dementia disorders Disease control Diseases Drug therapy Drugs Glutamate receptors Hypotheses Immunotherapy Inflammation Magnetic resonance imaging Medical research Memory Metabolism N-methyl-D-aspartate N-Methyl-D-aspartic acid receptors Neurodegeneration Neurodegenerative diseases Neuroinflammation Neuroprotection Neurotransmitters Pathogenesis Peptides Pharmaceutical industry Product development Psychological symptoms Reason Review Signs and symptoms Tau protein Time Trends United States > US Neuroprotection Anti-tau Alzheimer disease Anti-amyloid Neuroinflammation Cognitive enhancement Clinical trials of drugs
ISSN:	1423-0127, 1021-7770, 1423-0127
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!